About US
Contact us
-
Catalent and Adamas Pharmaceuticals Enter Phase III Clinical Trials Manufacturing AgreementCatalent Pharma Solutions, the global leader in development solutions and advanced delivery technologies for drug, biologic and consumer health products, andAdamas Pharmaceuticals Inc., have announced2014/1/10
-
Horizon and AstraZeneca collaborate on development of new cancer drugsUK-based Horizon Discovery and British-Swedish drug manufacturer AstraZeneca have entered into a research, collaboration and licensing agreement to explore a range of oncology-relevant genotypes in or2014/1/9
-
Immunocore and MedImmune Enter Immunother​apy Agreement to Develop Novel Cancer TherapiesImmunocore Ltd, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, has entered into an oncology research collaboration and licensing agreement2014/1/9
-
FDA grants fast-track status to Peregrine's bavituximab for lung cancer treatmentThe US Food and Drug Administration (FDA) has granted fast-track designation for Peregrine Pharmaceuticals' lead investigational immunotherapy 'bavituximab' to treat patients with second-line non-smal2014/1/8
-
Apogenix to Present Phase II Results with APG101 for the Treatment of Recurrent GlioblastomaThomas Hoeger, PhD, Chief Executive Officer,Agogenix, will present the results of the completed Phase II efficacy trial in patients with recurrent glioblastoma at the Biotech Showcase(TM) in San Franc2014/1/8
-
Agilis and Intrexon partner to develop DNA-based therapeutics for rare genetic diseaseUS-based synthetic biology companies Agilis Biotherapeutics and Intrexon have entered into an exclusive channel collaboration (ECC) agreement to develop DNA-based therapeutics for Friedreich's ataxia2014/1/7
-
FIT Biotech to start trial of potential HIV vaccine this yearFinland-based FIT Biotech has developed a new vaccine for the treatment of human immunodeficiency virus (HIV). The new vaccine will be tested in hundreds of HIV patients in a large clinical trial, wh2014/1/7
-
Bayer's hot-selling Eylea runs into a roadblock in its home marketSales ofBayer'sEyleahave taken off since the EU greenlighted the eye drug in late in 2012. But now,Germany's cost watchdog has thrown up a roadblock for the second time. Thursday, the German Institute2014/1/6
-
GSK Adds Detailed Clinical Trial Data to Multi-Sponsor Request System as Part of Commitment to Data TransparencyGlaxoSmithKline (GSK) has added its anonymised patient-level data from the online request system it launched in May 2013 to a new multi-sponsor request system (clinicalstudydatarequest.com) that inclu2014/1/6
-
Genzyme Receives Complete Response Letter from FDA on Lemtrada (Alemtuzumab) ApplicationSanofi and its subsidiary Genzyme has received a Complete Response Letter from FDA for its supplemental Biologics License Application seeking approval of Lemtrada (alemtuzumab) for the treatment of re2014/1/3